Gilead Ramps Up For Ambrisentan; Calls For 75 To 100 Sales Reps
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to go toe-to-toe with PAH competitors, CEO tells JP Morgan Healthcare Conference.
You may also be interested in...
Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
Bischofberger discusses how darusentan could complement recently approved Letairis in the hypertension market, and how Gilead plans to develop its integrase inhibitor elvitegravir, a potential competitor to Merck’s Isentress.
Gilead Executive VP-R&D Norbert Bischofberger: An Interview With “The Pink Sheet” DAILY (Part 2 of 3)
Bischofberger discusses how darusentan could complement recently approved Letairis in the hypertension market, and how Gilead plans to develop its integrase inhibitor elvitegravir, a potential competitor to Merck’s Isentress.
Actelion Will Take Novel Sleep Therapy Into Phase III This Year
The Swiss company, known for its pulmonary hypertension dominance, welcomes awareness-raising competition from new entrants like Gilead, CFO Oakley says.